Apremilast therapy increases CD39+CD4+ T cells in peripheral blood of patients with psoriatic disease: a retrospective observational pilot study
Rheumatology International · 06.05.2026 · 46 (5)
DOI: 10.1007/s00296-026-06114-3 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Rheumatology International, online erschienen am 06.05.2026. Verfasst von Athanasios Mavropoulos und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Clinical Immunology, Faculty of Medicine, University of Thessaly, Larissa, Greece. Hauptthemen laut MEDLINE: Apyrase, CD4-Positive T-Lymphocytes, Psoriasis, Thalidomide. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Thessaly Central Library.
Abstract (Originalsprache)
Psoriasis and psoriatic arthritis (PsA) are chronic inflammatory diseases, recognized as one entity, termed psoriatic disease (PsD). CD39 is an ectonucleotidase that hydrolyzes ATP to adenosine and is expressed on a human Treg sub-population capable of exerting interleukin (IL-) 17 suppression. We aimed to investigate the effect of apremilast on CD39 expression in T cells from patients with PsD. Peripheral blood mononuclear cells (PBMCs) were analyzed by multicolor flow cytometry and appropriate monoclonal antibodies. Intracellular cytokine production of PBMCs was measured after in vitro PMA plus ionomycin stimulation. At 6 weeks post-treatment , apremilast inhibited IL-17 and interferon-γ (IFNγ) production, increased IL-10 production in both CD4+T cells and CD4-T cells, and inhibited IL-6 production in CD4-T cells. At baseline, levels of CD4+CD39+ cells were decreased in patients compared to controls. At 6 weeks post-treatment, CD4+CD39+ cells increased. Furthermore, CD4+CD39+ cells producing IL-10 increased in patients who achieved a PASI response. A significant proportion of IL-10-producing CD39+ cells were CD56-CD11c- cells. CD4+FoxP3+ cells were decreased in patients compared to controls. At 6 weeks post-treatment CD4+FoxP3+ cells, and CD4+FoxP3+CD39+ cells increased, although CD4+CD25hiFoxP3+ Treg cells did not change significantly. If confirmed in larger studies, CD4+CD39+ cells producing IL-10 could likely become associated with the response to apremilast.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Clinical Immunology, Faculty of Medicine, University of Thessaly, Larissa, Greece.
- Department of Neurology, Faculty of Medicine, University of Thessaly, Larissa, Greece.
- Department of Dermatology, Faculty of Medicine, University of Thessaly, Larissa, Greece.
- IASO General Hospital, Larissa, Greece.
- Department of Rheumatology and Clinical Immunology, Faculty of Medicine, University of Thessaly, Larissa, Greece. bogdanos@med.uth.gr.
Förderung
- University of Thessaly Central Library
Zitieren
APA
Mavropoulos, A., Tsiogkas, S. G., Simopoulou, T., Dardiotis, E., Zafiriou, E., Sakkas, L. I., & Bogdanos, D. P. (2026). Apremilast therapy increases CD39+CD4+ T cells in peripheral blood of patients with psoriatic disease: a retrospective observational pilot study. Rheumatology International, 46(5). https://doi.org/10.1007/s00296-026-06114-3
Vancouver
Mavropoulos A, Tsiogkas SG, Simopoulou T, Dardiotis E, Zafiriou E, Sakkas LI, et al. Apremilast therapy increases CD39+CD4+ T cells in peripheral blood of patients with psoriatic disease: a retrospective observational pilot study. Rheumatology International. 2026;46(5). doi:10.1007/s00296-026-06114-3
BibTeX
@article{Mavropoulos2026,
author = {Mavropoulos, Athanasios and Tsiogkas, Sotirios G and Simopoulou, Theodora and Dardiotis, Efthimios and Zafiriou, Efterpi and Sakkas, Lazaros I and Bogdanos, Dimitrios P},
title = {Apremilast therapy increases CD39+CD4+ T cells in peripheral blood of patients with psoriatic disease: a retrospective observational pilot study},
journal = {Rheumatology International},
year = {2026},
volume = {46},
number = {5},
doi = {10.1007/s00296-026-06114-3}
}
EUVIMED